HSR are a common adverse event in patients rechallenged with carboplatin for ROC Carboplatin-PLD is associated with a lower risk of developing HSR compared to other doublets Several strategies have been developed to continue platinum-based therapy in these patients. Cisplatin rechallenge in patients with carboplatin HSR is a safe and feasible approach. In patients treated with cisplatin without a carboplatin-related HSR, a low rate of cisplatin-related HSR has been detected.